Completed PHASE3 INTERVENTIONAL NCT00005884

Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer

Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial

Sponsor: National Cancer Institute (NCI)

Updated 6 times since 2017 Last updated: Dec 12, 2019 Primary completion: Dec 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Non-melanomatous Skin Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Wisconsin, Madison

Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.